Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARCT-021
- Development stage
- Discontinued
- Lead developer
- Arcturus Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ARCT-021 is a self-amplifying mRNA (sa-mRNA) vaccine candidate developed by Arcturus Therapeutics for the prevention of COVID-19. It utilizes the STARR self-replicating mRNA technology combined with LUNAR lipid nanoparticle delivery to enhance and prolong antigen expression, enabling effective vaccination at lower doses. The vaccine encodes both the replication complex of Venezuelan equine encephalitis virus (VEEV) and the SARS-CoV-2 spike protein, targeting myocytes and dendritic cells to induce robust humoral and cellular immune responses. Clinical trials demonstrated that ARCT-021 was immunogenic with a favorable safety profile in both younger and older adults, eliciting neutralizing antibodies as well as CD4+ Th1-biased T-cell responses. Despite promising early results, development for COVID-19 was discontinued after Phase 2 trials[1][2][3][4][5][6][7].
- Other names
- Coronavirus Vaccine - Arcturus TherapeuticsLUNAR-COV19LUNAR-COV-19LUNAR-COV 19
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on ARCT-021.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARCT-021.